Antion Biosciences SA announced that it will receive a preferred equity round of funding on January 11, 2022. The transaction will include participation from new investor Allogene Therapeutics, Inc. As part of the transaction, Allogene Therapeutics, Inc. will take a seat on board of directors of the company.